CN101513407A - Application of naloxone and composition thereof in preparing drug for treating cancer - Google Patents
Application of naloxone and composition thereof in preparing drug for treating cancer Download PDFInfo
- Publication number
- CN101513407A CN101513407A CNA2009100110301A CN200910011030A CN101513407A CN 101513407 A CN101513407 A CN 101513407A CN A2009100110301 A CNA2009100110301 A CN A2009100110301A CN 200910011030 A CN200910011030 A CN 200910011030A CN 101513407 A CN101513407 A CN 101513407A
- Authority
- CN
- China
- Prior art keywords
- naloxone
- allylnoroxymorphone
- application
- hydrochloride
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of treating tumor by adopting an immunization therapy method, and particularly relates to application of naloxone or hydrochloride thereof or composition of the naloxone or the hydrochloride thereof with methionine enkephalin in preparing a drug for treating cancer. The application of the naloxone in preparing the drug for treating the cancer is characterized in that the naloxone and the hydrochloride thereof or the composition of the naloxone and the hydrochloride thereof and the methionine enkephalin are applied to preparing the drug for treating the cancer. The drug can be prepared into tablets, capsules, spraying agent, aerosol and eye drops. The application aims to fill the blank on the research of treating the cancer by using the naloxone and the hydrochloride thereof or/and the composition of the naloxone and the hydrochloride thereof and the methionine enkephalin.
Description
Technical field:
The invention belongs to and adopt immunization therapy ruling by law to treat the technical field of tumor, particularly relate to a kind of Allylnoroxymorphone or its hydrochlorate, make up separately or with met-enkephalin, be prepared into the application that medicine is treated cancer.
Background technology:
Allylnoroxymorphone, English name is Naltrexone, has another name called nalorphine, is the Hydromorphinol ketone derivatives, it or its hydrochlorate, its chemical constitution and morphine are similar, are single-minded morphine receptor antagonisies, are stereospecificity with morphine receptor and combine.Be a kind of clinical treatment medicine that has passed through state approval at present, its benefit is exactly that side effect is little, and safety range is very big, is the widest opiate receptor antagonistic of present clinical practice.Be mainly used in: 1. save the narcosis analgesic acute poisoning, the respiration inhibition of this class medicine of antagonism, and patient is revived.2. the residual action of antagonism narcosis analgesic.Neonate is influenced by narcosis analgesic in its parent and causes respiration inhibition.3. rescue acute alcoholism.4. be the narcosis analgesic addict to doubting.5. the short effect of waking up may activate physiological awakening system by the cholinergic effect and make patient clear-headed, is used for reviving after the operation of morphine class anaesthetic, and general anesthesia wakens and shock and some coma patient.6, be used to use Allylnoroxymorphone to treat the disturbance of consciousness that diseases such as apoplexy, alcoholism, drug abuse cause, also be used for the treatment of cerebral arteriosclerosis/vertigo etc., the treatment of central excitation or trophic nerve is arranged.
Therefore, up to the present, the research of Allylnoroxymorphone aspect treatment tumor or raising body immunity yet there are no any report.
Summary of the invention:
Goal of the invention: the invention provides a kind of Allylnoroxymorphone or its hydrochlorate and compositions thereof, as the application of preparation treatment cancer drug, its purpose is to solve fills up the blank that Allylnoroxymorphone is studied in this respect.
Technical scheme: the present invention is achieved by the following technical solutions:
Allylnoroxymorphone is characterized in that as the application of preparation treatment cancer drug: Allylnoroxymorphone and hydrochlorate thereof, have another name called nalorphine, and be the Hydromorphinol ketone derivatives, it is as the medicine of treatment cancer.
A kind of Allylnoroxymorphone and met-enkephalin compositions are as the application of preparation treatment cancer drug.
According to above-mentioned Allylnoroxymorphone and with the application of met-enkephalin compositions as preparation treatment cancer drug, medicine is made tablet, capsule, spray, aerosol and eye drop.
Advantage and effect: further study by the inventor, the body immune system cell, as: the T cell, the NK cell, there is the Allylnoroxymorphone receptor in surfaces such as macrophage, Allylnoroxymorphone by with above-mentioned receptors bind, immunologic function is bred and is improved in activation that can the immune stimulatory cell.Use Allylnoroxymorphone to be applied to treat the research of terminal cancer through the inventor, obtain certain therapeutic effect.
The specific embodiment:
Be described in detail as follows below by specific embodiment:
1, pharmacological action;
Allylnoroxymorphone is all bigger than morphine or enkephalin with the opium affinity, itself almost there is not the effect of morphine sample agonist, inject the low dose of effect that can block the morphine class rapidly, eliminate morphine class drug intoxication symptom, morphine has been tolerated the addict with occurring withdrawal symptom immediately behind this medicine.The clinical acute poisoning that is used for narcosis analgesic is the important drugs of analgesic being carried out pharmacological research.Naloxone is as a species specificity opiate receptor antagonist, can effectively treat the delayed ischemic neurological deficits due to multiple infarct and other cerebral ischemia, and cognitive activities such as learning and memory are had certain positivity influence.An amount of Allylnoroxymorphone by with the T cell of body immune system, the NK cell, the Allylnoroxymorphone receptors bind on surface such as macrophage stimulates the activation of above-mentioned cell, propagation, thereby produce killing activity to tumor cell.
Embodiment 1:
Allylnoroxymorphone is disposed the concentration of 0.1 microgram/ml, by 0.1 microgram/kg body weight/every day to 10 milligram/use kg body weight/every day.
Embodiment 2:
The hydrochlorate of Allylnoroxymorphone is disposed the concentration of 0.1 microgram/ml, by 0.1 microgram/kg body weight/every day to 10 milligram/use kg body weight/every day.
Embodiment 3:
Allylnoroxymorphone is disposed the concentration of 0.1 microgram/ml, and the concentration of met-enkephalin is 0.0001 milligram/ml, these two kinds of solution is mixed, by 0.1 microgram/kg body weight/every day to 10 milligram/use kg body weight/every day.
Embodiment 4:
The hydrochlorate of Allylnoroxymorphone is disposed the concentration of 0.1 microgram/ml, and the concentration of met-enkephalin is 0.0001 milligram/ml, these two kinds of solution is mixed, by 0.1 microgram/kg body weight/every day to 10 milligram/use kg body weight/every day.
The solution that above embodiment obtains is configured to injection respectively.By voluntary patient 12 people are experimentized, this 12 people is age-based, sex is equally divided into two groups, one group is experimental group, another group is matched group, adopt the medicine of embodiment 1～4 to treat to experimental group, matched group adopts at present other medicine to treat, and experimental result shows that experimental group obviously is better than matched group.
Patient Zhang, woman, 65 years old, suffer from cancer of pancreas late period, whole body shifts, ascites, clinical not treatment selection, lymphocyte subpopulation detects and to show patient CD4+T cell obviously descend (25), CD8+T cell (comprise suppress cell) obviously rises (48), and CD4+T/CD8+T ratio obviously descends (0.52), NK obviously descend (2%), whole immune system is obviously unbalance, and life is at death's door.We adopt the Allylnoroxymorphone injection for treating, 30 milligrams/every day, continuous 3 months, patient's lymphocyte subpopulation detects and shows: the CD4+T cell is (35) obviously, CD8+T cell (comprise and suppress cell) obviously descends (25), CD4+T/CD8+T ratio obviously rises (1.4), NK obviously rise (8%).Patient's immune system is recovered nearly normal value, continues to keep treatment 3 months, and patient's life is saved, and recovers comprehensively.
The patient thanks certain, the woman 55 years old, suffers from breast cancer late period, whole body is transferred to bone marrow, clinical not treatment selection, lymphocyte subpopulation detects and shows that patient CD4+T cell obviously descends (18), CD8+T cell (comprise and suppress cell) obviously rise (52), CD4+T/CD8+T ratio obviously descend (0.34), NK obviously descends (3%), and whole immune system is obviously unbalance, and life is at death's door.We adopt the Allylnoroxymorphone injection for treating, 30 milligrams/every day, rose in the tenth day and added met-enkephalin 5mg/ days injection for curing every day continuous 3 months, patient's lymphocyte subpopulation detects and shows: the CD4+T cell is (38) obviously, CD8+T cell (comprise and suppress cell) obviously descends (35), CD4+T/CD8+T ratio obviously rises (1.1), NK obviously rise (7%).Patient's immune system is recovered nearly normal value, continues to keep treatment 3 months, and patient's life is saved, and recovers comprehensively.
The medicine of embodiment 1～4 gained is made tablet, capsule, spraying (aerosol) drop and eye drop, and with reference to 2005 pharmacopeia (two ones) preparation stability is investigated, meet national standard.
Claims (3)
1, Allylnoroxymorphone is characterized in that as the application of preparation treatment cancer drug: Allylnoroxymorphone and hydrochlorate thereof, have another name called nalorphine, and be the Hydromorphinol ketone derivatives, it is as the medicine of treatment cancer.
2, a kind of Allylnoroxymorphone and met-enkephalin compositions are as the application of preparation treatment cancer drug.
3, Allylnoroxymorphone according to claim 1 and 2 and with the application of met-enkephalin compositions as preparation treatment cancer drug, medicine is made tablet, capsule, spray, aerosol and eye drop.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2009100110301A CN101513407A (en) | 2009-04-03 | 2009-04-03 | Application of naloxone and composition thereof in preparing drug for treating cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2009100110301A CN101513407A (en) | 2009-04-03 | 2009-04-03 | Application of naloxone and composition thereof in preparing drug for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101513407A true CN101513407A (en) | 2009-08-26 |
Family
ID=41038129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2009100110301A Pending CN101513407A (en) | 2009-04-03 | 2009-04-03 | Application of naloxone and composition thereof in preparing drug for treating cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101513407A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102772784A (en) * | 2012-08-15 | 2012-11-14 | 单风平 | Application of naltrexone combined methionine enkephalin in preparing medicament for treating cancer |
| CN102784384A (en) * | 2012-08-23 | 2012-11-21 | 单风平 | Application of combination of low-dose naltrexone and methionine-enkephalin to preparation of anti-cancer drug |
| CN103695497A (en) * | 2013-12-20 | 2014-04-02 | 奇方(天津)医药科技有限公司 | Enzymatic preparation of naloxone and pharmaceutical composition thereof |
-
2009
- 2009-04-03 CN CNA2009100110301A patent/CN101513407A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102772784A (en) * | 2012-08-15 | 2012-11-14 | 单风平 | Application of naltrexone combined methionine enkephalin in preparing medicament for treating cancer |
| CN102784384A (en) * | 2012-08-23 | 2012-11-21 | 单风平 | Application of combination of low-dose naltrexone and methionine-enkephalin to preparation of anti-cancer drug |
| CN103695497A (en) * | 2013-12-20 | 2014-04-02 | 奇方(天津)医药科技有限公司 | Enzymatic preparation of naloxone and pharmaceutical composition thereof |
| CN103695497B (en) * | 2013-12-20 | 2014-09-17 | 奇方(天津)医药科技有限公司 | Enzymatic preparation of naloxone and pharmaceutical composition thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Phan et al. | Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review | |
| US20030147975A1 (en) | Pharmaceutical composition which produces irritation | |
| CN110573159A (en) | D-methadone and derivatives thereof for the treatment of disorders of the nervous system | |
| KR101969667B1 (en) | D-methadone for the treatment of psychiatric symptoms | |
| TW201912152A (en) | Compounds for treatment or prevention of disorders of the nervous system and symptoms and manifestations thereof, and for cyto-protection against diseases and aging of cells, and symptoms and manifestations thereof | |
| CN110478350A (en) | The application of bulleyaconitine A and its derivative in the preparation inhibition addicted drug of drug | |
| Mahesh et al. | Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods | |
| CN101513407A (en) | Application of naloxone and composition thereof in preparing drug for treating cancer | |
| CN109453162B (en) | Application of amentoflavone in preparation of medicine for protecting and/or repairing nerve cells, medicine composition and application | |
| US20120010125A1 (en) | Methods, compounds and pharmaceutical compositions for treating anxiety and mood disorders | |
| CN101829328B (en) | Drug for treating amphetamine-type exhilarant dependence syndrome and amphetamine-type exhilarant and opioid mixed dependence syndrome | |
| WO2005023256A1 (en) | Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome | |
| CN101147741A (en) | Medicine for giving up drug | |
| CN101543624B (en) | Purpose of Chilobrachys jingzhao toxin extract-jingzhao toxin-V(JZTX-V) in preparation of drug-breaking medicament | |
| EP3233825B1 (en) | Diarylmethylidene piperidine derivatives and their use as delta opioid receptor agonists | |
| CN103495172A (en) | Medicament for treating amphetamine type stimulant dependency and mixed dependency of amphetamine type stimulants and opiates substances | |
| CN112439051B (en) | Application of cyclic dipeptide in preparation of drugs for treating mental diseases | |
| CN100363006C (en) | Drug addiction-stopping formulation and preparation thereof | |
| EP2905021B1 (en) | Combination for the prophylaxis and treatment of behavioural, mental and cognitive disorders | |
| Han et al. | The common neurological basis and targeted therapeutic approaches for chronic pain and opioid addiction. | |
| KR101695052B1 (en) | Composition for treating vomiting or diarrhea comprising Raphanus sativus Linne seed extract | |
| CN106176740A (en) | The medical usage of the anti-addiction of corydalmine | |
| CN105998023B (en) | Application of demethylsinomenine in preparation of analgesic | |
| Stasiuk et al. | The NMDA receptor and new possibilities in antidepressant therapy | |
| Karandikar et al. | Comparative study of CNS effects of opium in homeopathic potencies with pentazocine in mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20090826 |